In a groundbreaking stride against HIV/AIDS, a South African company is spearheading a revolutionary approach to prevention with an injectable drug, Cabotegravir long-acting (CAB LA). This World AIDS Day brought hope as trials showed promising results, particularly in a nation facing one of the world’s highest HIV rates. This development is a potential game-changer, offering a discreet and user-friendly alternative to conventional oral PrEP.

The HIV Landscape in South Africa

South Africa has been at the forefront of the global battle against HIV, with more than seven million people currently living with the virus. Despite substantial progress in treatment, the country witnessed around 160,000 new infections last year, highlighting the persistent challenges. The introduction of an injectable pre-exposure prophylaxis (PrEP) represents a beacon of hope, especially for those at high risk.

The Injectable PrEP Advantage

CAB LA, the injectable PrEP, demonstrates a paradigm shift in HIV prevention. Unlike its daily oral counterpart, this variant lasts for two months, offering a discreet and user-friendly option. Linda-Gail Bekker, CEO of the Desmond Tutu HIV Foundation, emphasizes an 89% reduction in HIV infections among women in Africa using injectable PrEP compared to oral PrEP, underlining its superiority.

Affordability and Accessibility Challenges

While approved for use in South Africa, the injectable’s cost remains a significant hurdle, priced at several thousand dollars per shot. The company producing it has shared licenses to address this concern. However, challenges persist in affordability and manufacturing capacity that need concerted efforts for widespread accessibility.

International Collaboration for Progress

International collaboration is pivotal in introducing CAB LA in South Africa, especially with the United States (U.S.). Dr. John Nkengasong, the U.S. Global AIDS Coordinator, acknowledges the evolving landscape in the fight against HIV, highlighting the innovation brought by long-acting PrEP injectables.

South Africa is gearing up for a pilot project in early 2024 to evaluate the implementation of injectable PrEP, specifically targeting adolescent girls and young women. Initially slated for 2023, as per VOA reports, these projects experienced delays, pushing the launch to early 2024. Spearheaded by Unitaid, this pivotal demonstration project addresses the intricacies of introducing this innovative prevention method from clinical settings into local communities. Despite the setbacks, Chief Investigator Pontiano Kaleebu emphasizes the importance of developing an HIV vaccine for Africa.

Implementation Challenges and Future Outlook

Implementing injectable PrEP beyond clinical settings presents challenges. Trained nurses will likely administer the injections, requiring additional training. However, the larger question revolves around decentralized delivery models and community acceptance. Community ‘shot clinics’ are proposed, offering a potential solution for administering injectable PrEP in a more accessible and user-friendly manner.

Dr. Francois Venter, divisional director of the research institute Ezintsha, remarks, “There needs to be a bit of a stock-taking before we do that. But our patients are going to be pushing us to go very fast.”

The Impact on the Ground 

Amidst the groundbreaking developments in HIV prevention, NGOs like the Treatment Action Campaign (TAC) continue to play a crucial role in South Africa. TAC, a key advocate for access to HIV treatment, is poised to adapt its strategies with the anticipated launch of injectable PrEP in early 2024. This innovative preventive method aligns with TAC’s mission, providing an opportunity to enhance outreach and education efforts. The longer-acting and user-friendly nature of injectable PrEP could empower NGOs like TAC to strengthen their campaigns, offering additional tools in the ongoing fight against HIV/AIDS. Overall, these advancements present NGOs with new avenues to contribute effectively to eradicating HIV in South Africa.

Tracking and Measuring Success

Monitoring the usage patterns of oral and injectable PrEP presents a significant challenge because these preventive methods are constantly evolving. Therefore, developing more effective metrics to assess the impact of PrEP on a population level could be necessary.

Additionally, the effectiveness of injectable PrEP depends on its integration with extensive sexual and reproductive health services. It is crucial to educate communities about the various options available for HIV prevention, thereby linking injectable PrEP with empowering messages about wellness.

South Africa Taking the Lead

South Africa’s leading role in the development and implementation of injectable PrEP marks a pivotal moment in the fight against HIV. As the nation gears up for pilot projects, the prospect of a discreet, user-friendly, and more effective prevention method brings renewed hope for a future where HIV is no longer a pervasive threat. The collaboration between local initiatives and global support underscores the collective commitment to eradicating HIV and creating a healthier world.

– Ed Santana

Photo: unsplash